IFNG and neoplasm: While the administration of MDSC-depleting antibodies (RB6-8C5) alone did not have any detectable effect on cytokine release with any tumor cell line, we observed a remarkable increase in the D5 tumor-specific IFN-γ secretion from TVDLN in mice treated with the combination of LRAST and RB6-8C5 mAb (8193 pg/mL; Figure 4a).